Phathom Pharmaceuticals Stock Fundamentals
| PHAT Stock | USD 11.78 0.12 1.03% |
Phathom Pharmaceuticals' fundamental analysis aims to assess its intrinsic value by examining key economic and financial indicators - such as cash flow records, changes in balance sheet accounts, income statement trends, financial ratios, and relevant microeconomic factors affecting Phathom Stock price.
At this time, Phathom Pharmaceuticals' Cost Of Revenue is comparatively stable compared to the past year. Phathom | Select Account or Indicator | Build AI portfolio with Phathom Stock |
Phathom Pharmaceuticals Company Return On Equity Analysis
Phathom Pharmaceuticals' Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Phathom Pharmaceuticals Return On Equity | -34.89 |
Most of Phathom Pharmaceuticals' fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Phathom Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Phathom Total Stockholder Equity
Total Stockholder Equity |
|
Based on the latest financial disclosure, Phathom Pharmaceuticals has a Return On Equity of -34.89. This is 45.56% higher than that of the Pharmaceuticals sector and 4.31% lower than that of the Health Care industry. The return on equity for all United States stocks is notably higher than that of the company.
Phathom Pharmaceuticals Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Phathom Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Phathom Pharmaceuticals value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Phathom Pharmaceuticals competition to find correlations between indicators driving Phathom Pharmaceuticals's intrinsic value. More Info.Phathom Pharmaceuticals is rated below average in return on equity category among its peers. It also is rated below average in return on asset category among its peers . At this time, Phathom Pharmaceuticals' Return On Equity is comparatively stable compared to the past year. Comparative valuation analysis is a catch-all technique that is used if you cannot value Phathom Pharmaceuticals by discounting back its dividends or cash flows. It compares the stock's price multiples to nearest competition to determine if the stock is relatively undervalued or overvalued.Phathom Return On Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Phathom Pharmaceuticals' direct or indirect competition against its Return On Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Phathom Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Phathom Pharmaceuticals by comparing valuation metrics of similar companies.Phathom Pharmaceuticals is currently under evaluation in return on equity category among its peers.
Phathom Pharmaceuticals Current Valuation Drivers
We derive many important indicators used in calculating different scores of Phathom Pharmaceuticals from analyzing Phathom Pharmaceuticals' financial statements. These drivers represent accounts that assess Phathom Pharmaceuticals' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Phathom Pharmaceuticals' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 1.1B | 727.8M | 438.9M | 468.3M | 513.0M | 665.2M | |
| Enterprise Value | 865.4M | 635.9M | 380.6M | 225.9M | 259.8M | 246.8M |
Phathom Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Phathom Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Phathom Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Phathom Fundamentals
| Return On Equity | -34.89 | ||||
| Return On Asset | -0.59 | ||||
| Profit Margin | (2.90) % | ||||
| Operating Margin | (1.52) % | ||||
| Current Valuation | 892.11 M | ||||
| Shares Outstanding | 70.94 M | ||||
| Shares Owned By Insiders | 4.19 % | ||||
| Shares Owned By Institutions | 83.24 % | ||||
| Number Of Shares Shorted | 14 M | ||||
| Price To Book | 25.37 X | ||||
| Price To Sales | 7.33 X | ||||
| Revenue | 55.25 M | ||||
| Gross Profit | 99.11 M | ||||
| EBITDA | (261.52 M) | ||||
| Net Income | (334.33 M) | ||||
| Cash And Equivalents | 207.39 M | ||||
| Cash Per Share | 5.39 X | ||||
| Total Debt | 554.95 M | ||||
| Debt To Equity | 2.43 % | ||||
| Current Ratio | 9.93 X | ||||
| Book Value Per Share | (5.79) X | ||||
| Cash Flow From Operations | (266.77 M) | ||||
| Short Ratio | 12.84 X | ||||
| Earnings Per Share | (4.67) X | ||||
| Target Price | 21.38 | ||||
| Number Of Employees | 427 | ||||
| Beta | 0.44 | ||||
| Market Capitalization | 835.72 M | ||||
| Total Asset | 378.32 M | ||||
| Retained Earnings | (1.26 B) | ||||
| Working Capital | 274.41 M | ||||
| Net Asset | 378.32 M |
About Phathom Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Phathom Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Phathom Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Phathom Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 21.1 M | 22.1 M | |
| Total Revenue | 55.3 M | 58 M | |
| Cost Of Revenue | 8 M | 8.4 M | |
| Stock Based Compensation To Revenue | 0.44 | 0.41 | |
| Research And Ddevelopement To Revenue | 0.62 | 0.59 | |
| Capex To Revenue | 2.16 | 1.92 | |
| Revenue Per Share | 0.87 | 0.92 | |
| Ebit Per Revenue | (5.02) | (5.27) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Phathom Stock Analysis
When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.